Pooled Testing for SARS-CoV-2 in Hospitalized Patients.

David Mastrianni, Richard Falivena, Timothy Brooks, Brian McDermott, Josenia Tan, Richard Vandell, Michael Holland
Author Information
  1. David Mastrianni: Administration, Saratoga Hospital, Saratoga Springs, New York.
  2. Richard Falivena: Administration, Saratoga Hospital, Saratoga Springs, New York.
  3. Timothy Brooks: Department of Emergency Medicine, Saratoga Hospital, Saratoga Springs, New York.
  4. Brian McDermott: Division of Infectious Disease, Saratoga Hospital, Saratoga Springs, New York.
  5. Josenia Tan: Department of Pathology and Laboratory Medicine, Sarato-ga Hospital, Saratoga Springs, New York.
  6. Richard Vandell: Department of Pathology and Laboratory Medicine, Sarato-ga Hospital, Saratoga Springs, New York.
  7. Michael Holland: Department of Occupational Medicine, Saratoga Hospital, Saratoga Springs, New York.

Abstract

Viral testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly early in the COVID-19 pandemic, was limited by supply of reagents. We pooled nasopharyngeal samples from patients at low risk of SARS-CoV-2 infection in groups of 3 for testing. Three weeks of testing using this strategy resulted in 530 patient tests in 179 cartridges; 4 positive test groups required the use of 11 additional cartridges with an overall positive rate of 0.8% in a low-risk population. This strategy resulted in the use of 340 fewer cartridges than if each test were performed on one patient sample. Pooled testing of low-risk populations allows for continued testing even when supplies are relatively scarce.

MeSH Term

Betacoronavirus
COVID-19
Coronavirus Infections
DNA, Viral
Genetic Testing
Humans
Inpatients
Pandemics
Pneumonia, Viral
SARS-CoV-2

Chemicals

DNA, Viral